Early phase 1 data suggest that in vivo, off-the-shelf CAR T therapy may be feasible in multiple myeloma, offering the ...

Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...

Patients treated in an outpatient setting who later required admission spent an average of 12.1 days in the hospital, ...

Autolus Therapeutics is working with Cellares to assess automated CAR T manufacturing to support rising demand for its FDA-approved therapy.

Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...

Improved QOL is observed in patients over two years post-infusion and those without disease progression, highlighting the importance of long-term monitoring. A recent study reveals CAR T-cell therapy ...

Efforts to develop off-the-shelf (OTS) cell therapies are accelerating across global biotech, as researchers aim to make next ...

Chimeric antigen receptor (CAR) T-cell therapy is an innovative cancer treatment that engineers a patient’s own T cells to target and destroy cancer cells. While the field has sparked significant ...

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

A novel in vivo CD19 CAR-T therapy achieved complete remission in a DLBCL patient without lymphodepletion, showing sustained efficacy over three months. The therapy demonstrated safety, with no ...